Found: 25
Select item for more details and to access through your institution.
Phase II study of avelumab in multiple relapsed/refractory germ cell cancer.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 748, doi. 10.1007/s10637-019-00805-4
- By:
- Publication type:
- Article
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 738, doi. 10.1007/s10637-019-00768-6
- By:
- Publication type:
- Article
An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 784, doi. 10.1007/s10637-019-00737-z
- By:
- Publication type:
- Article
Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 722, doi. 10.1007/s10637-018-0714-6
- By:
- Publication type:
- Article
Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1–ALK fusion: a case report.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 791, doi. 10.1007/s10637-019-00742-2
- By:
- Publication type:
- Article
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 755, doi. 10.1007/s10637-019-00797-1
- By:
- Publication type:
- Article
Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 731, doi. 10.1007/s10637-019-00735-1
- By:
- Publication type:
- Article
Inhibition of AKT signalling by benzoxazine derivative LTUR6 through the modulation of downstream kinases.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 779, doi. 10.1007/s10637-019-00726-2
- By:
- Publication type:
- Article
Correction to: A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-<sub>XL</sub>.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice
Cyclodextrin polymers decorated with RGD peptide as delivery systems for targeted anti-cancer chemotherapy.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 771, doi. 10.1007/s10637-018-0711-9
- By:
- Publication type:
- Article
Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 763, doi. 10.1007/s10637-018-0710-x
- By:
- Publication type:
- Article
Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 711, doi. 10.1007/s10637-018-0706-6
- By:
- Publication type:
- Article
A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 684, doi. 10.1007/s10637-018-0703-9
- By:
- Publication type:
- Article
A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 702, doi. 10.1007/s10637-018-0696-4
- By:
- Publication type:
- Article
Mass balance, routes of excretion, and pharmacokinetics of investigational oral [<sup>14</sup>C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 666, doi. 10.1007/s10637-018-0693-7
- By:
- Publication type:
- Article
A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 658, doi. 10.1007/s10637-018-0690-x
- By:
- Publication type:
- Article
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 693, doi. 10.1007/s10637-018-0688-4
- By:
- Publication type:
- Article
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 674, doi. 10.1007/s10637-018-0674-x
- By:
- Publication type:
- Article
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 636, doi. 10.1007/s10637-018-0668-8
- By:
- Publication type:
- Article
Relationship between expression of XRCC1 and tumor proliferation, migration, invasion, and angiogenesis in glioma.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 646, doi. 10.1007/s10637-018-0667-9
- By:
- Publication type:
- Article
Hexane partition from Annona crassiflora Mart. promotes cytotoxity and apoptosis on human cervical cancer cell lines.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 602, doi. 10.1007/s10637-018-0657-y
- By:
- Publication type:
- Article
The Monocarboxylate transporter inhibitor Quercetin induces intracellular acidification in a mouse model of Glioblastoma Multiforme: in-vivo detection using magnetic resonance imaging.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 595, doi. 10.1007/s10637-018-0644-3
- By:
- Publication type:
- Article
CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 625, doi. 10.1007/s10637-018-0661-2
- By:
- Publication type:
- Article
Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 616, doi. 10.1007/s10637-018-0651-4
- By:
- Publication type:
- Article